Simon Kerry PhD MBA, Chief Executive Officer
Simon is a business professional with over twelve years experience in creating and developing innovative life-science companies. Before joining Karus in early-2006, he was Director of Business Development at Ablynx (Ghent, Belgium), where he was responsible for securing a number of key deals with major pharmaceutical companies. Prior to Ablynx, Simon was Director of Business Development at Isogenica (Cambridge, UK) and Active Biotech (Lund, Sweden) and has held other key commercial appointments at Actinova and Actigen (both Cambridge, UK) and at CAMR (Salisbury, UK). Simon has a PhD in medicinal chemistry and an executive MBA from Loughborough University Business School.
Stephen Shuttleworth PhD FRSC, Chief Scientific Officer
Stephen is an R&D leader with over a decade of experience in the pharmaceutical industry. Stephen has established a strong track-record in R&D management with a number of high-caliber companies on both sides of the Atlantic, including Celltech-Chiroscience (Cambridge, UK), Shire Pharmaceuticals Inc. (Montreal, Canada), Amgen, Inc. (San Francisco, California) where he was Associate Director of Chemistry, and Piramed Ltd (Slough, UK) where he was Director of Chemistry and PI3K Program Leader. Prior to joining Karus he was Head of New Projects Development at Cancer Research UK. Stephen obtained his BSc and PhD in Chemistry at the University of Liverpool. He has authored more than 70 publications and patents, and is a Fellow of the Royal Society of Chemistry.
Karus Therapeutics Ltd
John Fairclough Centre
University of Southampton
Highfield
Southampton
Hampshire SO17 1BJ
United Kingdom